{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:42:06Z","timestamp":1759542126428},"reference-count":77,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2012,1,19]],"date-time":"2012-01-19T00:00:00Z","timestamp":1326931200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"DOI":"10.1371\/journal.pcbi.1002359","type":"journal-article","created":{"date-parts":[[2012,1,19]],"date-time":"2012-01-19T21:55:16Z","timestamp":1327010116000},"page":"e1002359","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":26,"title":["HIV-1 Polymerase Inhibition by Nucleoside Analogs: Cellular- and Kinetic Parameters of Efficacy, Susceptibility and Resistance Selection"],"prefix":"10.1371","volume":"8","author":[{"given":"Max","family":"von Kleist","sequence":"first","affiliation":[]},{"given":"Philipp","family":"Metzner","sequence":"additional","affiliation":[]},{"given":"Roland","family":"Marquet","sequence":"additional","affiliation":[]},{"given":"Christof","family":"Sch\u00fctte","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2012,1,19]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"925 13","DOI":"10.1038\/nrd703","article-title":"Strategies in the design of antiviral drugs.","volume":"1","author":"ED Clercq","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.2174\/138161206776361156","article-title":"Antiviral therapy targeting viral poly-merase.","volume":"12","author":"CH Tsai","year":"2006","journal-title":"Curr Pharm Des"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1056\/NEJM198406143102401","article-title":"Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir.","volume":"310","author":"SE Straus","year":"1984","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJM198406143102402","article-title":"A double blind study of oral acyclovir for suppression of recurrences of genital herpes simplex 3 virus infection.","volume":"310","author":"JM Douglas","year":"1984","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJM198707233170401","article-title":"The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.","volume":"317","author":"MA Fischl","year":"1987","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2174\/1568026043388358","article-title":"Biochemical and mechanistic basis for the activity of nucleoside analogue inhibitors of HIV reverse transcriptase.","volume":"4","author":"GR Painter","year":"2004","journal-title":"Curr Top Med Chem"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"e1000720","DOI":"10.1371\/journal.pcbi.1000720","article-title":"Drug-class specific impact of antivirals on the reproductive capacity of HIV.","volume":"6","author":"M von Kleist","year":"2010","journal-title":"PloS Comput Biol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"40847","DOI":"10.1074\/jbc.M106743200","article-title":"Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase.","volume":"276","author":"AA Johnson","year":"2001","journal-title":"J Biol Chem"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/nrd1201","article-title":"Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective.","volume":"2","author":"W Lewis","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1128\/AAC.01229-10","article-title":"Pre-steady-state kinetic analysis of the incorporation of anti-HIV nucleotide analogs catalyzed by human x- and y-family DNA polymerases.","volume":"55","author":"JA Brown","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"25159","DOI":"10.1074\/jbc.M703972200","article-title":"Enzymatic therapeutic index of acyclovir. Viral versus human polymerase gamma specificity.","volume":"282","author":"JW Hanes","year":"2007","journal-title":"J Biol Chem"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.virusres.2007.12.015","article-title":"Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase.","volume":"134","author":"L Menndez-Arias","year":"2008","journal-title":"Virus Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.biocel.2004.02.028","article-title":"Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs).","volume":"36","author":"V Goldschmidt","year":"2004","journal-title":"Int J Biochem Cell Biol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-5793(91)81089-Q","article-title":"Factors contributing to the inhibition of HIV reverse transcriptase by chain-terminating nucleotides in vitro and in vivo.","volume":"291","author":"RS Goody","year":"1991","journal-title":"FEBS Lett"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1097-2765(00)80185-9","article-title":"A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase.","volume":"4","author":"PR Meyer","year":"1999","journal-title":"Mol Cell"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1128\/JVI.75.10.4832-4842.2001","article-title":"Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase.","volume":"75","author":"PL Boyer","year":"2001","journal-title":"J Virol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"8831","DOI":"10.1021\/bi034435l","article-title":"Prob-ing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis.","volume":"42","author":"AS Ray","year":"2003","journal-title":"Biochemistry"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"10292","DOI":"10.1021\/bi970512z","article-title":"Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC.","volume":"36","author":"R Krebs","year":"1997","journal-title":"Biochemistry"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jtbi.2010.05.006","article-title":"Development of a stochastic model for the efficacy of NRTIs using known mechanisms of action.","volume":"265","author":"S Khalili","year":"2010","journal-title":"J Theor Biol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1517\/13543784.13.8.933","article-title":"Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy.","volume":"13","author":"RW Buckheit","year":"2004","journal-title":"Expert Opin Investig Drugs"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.virusres.2007.12.021","article-title":"HIV-1 reverse transcriptase inhibitor resis-tance mutations and fitness: a view from the clinic and ex vivo.","volume":"134","author":"J Martinez-Picado","year":"2008","journal-title":"Virus Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1126\/science.1101786","article-title":"Evidence for positive epistasis in hiv-1.","volume":"306","author":"S Bonhoeffer","year":"2004","journal-title":"Science"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"e18375","DOI":"10.1371\/journal.pone.0018375","article-title":"Fitness ranking of individual mutants drives patterns of epistatic interactions in hiv-1.","volume":"6","author":"JP Martnez","year":"2011","journal-title":"PLoS One"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jmb.2004.01.030","article-title":"Excision of incorporated nucleotide analogue chain-terminators can diminish their inhibitory effects on viral RNA-dependent RNA polymerases.","volume":"337","author":"CM D'Abramo","year":"2004","journal-title":"J Mol Biol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1128\/AAC.00186-07","article-title":"Pyrophosphorolytic excision of nonobligate chain terminators by hepatitis C virus NS5B polymerase.","volume":"51","author":"J Deval","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"4984","DOI":"10.1073\/pnas.091324398","article-title":"Efficient pyrophosphorolysis by a hepatitis b virus polymerase may be a primer-unblocking mechanism.","volume":"98","author":"S Urban","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"e18204","DOI":"10.1371\/journal.pone.0018204","article-title":"HIV quasispecies dynamics during pro-active treatment switching: Impact on multi-drug resistance and resistance archiving in latent reservoirs.","volume":"6","author":"M von Kleist","year":"2011","journal-title":"PloS One"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1126\/science.6328660","article-title":"Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes.","volume":"225","author":"D Klatzmann","year":"1984","journal-title":"Science"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1126\/science.3016903","article-title":"Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy.","volume":"233","author":"S Koenig","year":"1986","journal-title":"Science"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"6710","DOI":"10.1128\/JVI.75.14.6710-6713.2001","article-title":"Plasmacytoid dendritic cells are highly susceptible to human immunodeficiency virus type 1 infection and release infectious virus.","volume":"75","author":"S Patterson","year":"2001","journal-title":"J Virol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1073\/pnas.102672999","article-title":"Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy.","volume":"99","author":"A Valentin","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.410390606","article-title":"Localization of HIV-1 in human brain using polymerase chain reaction\/in situ hybridization and immunocytochemistry.","volume":"39","author":"K Takahashi","year":"1996","journal-title":"Ann Neurol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"11514","DOI":"10.1073\/pnas.95.20.11514","article-title":"Drug concentration heterogeneity facilitates the evolution of drug resistance.","volume":"95","author":"TB Kepler","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.2174\/138161206776873572","article-title":"The influence of natural substrates and inhibitors on the nucleotide-dependent excision activity of HIV-1 reverse transcriptase in the infected cell.","volume":"12","author":"AJ Smith","year":"2006","journal-title":"Curr Pharm Des"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1128\/AAC.49.5.1761-1769.2005","article-title":"Intracellular substrates for the primer-unblocking reaction by human immunodeficiency virus type 1 reverse transcriptase: detection and quantitation in extracts from quiescent- and activated-lymphocyte subpopulations.","volume":"49","author":"AJ Smith","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00928361","article-title":"Physiological concentrations of purines and pyrimidines.","volume":"140","author":"TW Traut","year":"1994","journal-title":"Mol Cell Biochem"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1042\/cs0650635","article-title":"Importance of platelet-free preparations for evaluating lymphocyte nucleotide levels in inherited or acquired immunodeficiency syndromes.","volume":"65","author":"A Goday","year":"1983","journal-title":"Clin Sci (Lond)"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/978-1-4757-0390-0_36","article-title":"Nu1-cleotide levels in peripheral blood mononuclear cells of immunodeficient children: problems of measurement.","volume":"165 Pt B","author":"A Goday","year":"1984","journal-title":"Adv Exp Med Biol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/nsmb.1908","article-title":"Structural basis of HIV-1 resistance to AZT by excision.","volume":"17","author":"X Tu","year":"2010","journal-title":"Nat Struct Mol Biol"},{"key":"ref40","article-title":"HIV drug resistance database.","year":"2011"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/QAD.0b013e3280187505","article-title":"Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance muta-tions.","volume":"21","author":"FA Frankel","year":"2007","journal-title":"AIDS"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/jmv.10246","article-title":"Persistence of earlier HIV-1 drug resistance mutations at new treatment failure.","volume":"68","author":"V Svedhem","year":"2002","journal-title":"J Med Virol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1128\/AAC.44.4.920-928.2000","article-title":"A novel pheno- typic drug susceptibility assay for human immunodeficiency virus type 1.","volume":"44","author":"CJ Petropoulos","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0149-2918(00)90004-3","article-title":"Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.","volume":"22","author":"TN Kakuda","year":"2000","journal-title":"Clin Ther"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/jlb.62.1.138","article-title":"Inhibition of replication of HIV in primary monocyte\/macrophages by different antiviral drugs and comparative efficacy in lymphocytes.","volume":"62","author":"S Aquaro","year":"1997","journal-title":"J Leukoc Biol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1073\/pnas.89.5.1934","article-title":"Fifth mutation in human immunodefi-ciency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine.","volume":"89","author":"P Kellam","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1128\/AAC.38.6.1404","article-title":"Suscepti- bilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase in- hibitors.","volume":"38","author":"VW Byrnes","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1128\/JVI.00311-11","article-title":"Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide hiv reverse transcriptase inhibitors.","volume":"85","author":"JG Garca-Lerma","year":"2011","journal-title":"J Virol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1128\/JVI.01620-06","article-title":"Human immun- odeficiency virus type 1: resistance to nucleoside analogues and replicative capacity in primary human macrophages.","volume":"81","author":"D Perez-Bercoff","year":"2007","journal-title":"J Virol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nm.2111","article-title":"HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.","volume":"16","author":"MJ Buzon","year":"2010","journal-title":"Nat Med"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"8470","DOI":"10.1128\/JVI.02568-08","article-title":"Anal- ysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy.","volume":"83","author":"TP Brennan","year":"2009","journal-title":"J Virol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"026106","DOI":"10.1063\/1.3449300","article-title":"Simple genomes, complex interactions: epistasis in rna virus.","volume":"20","author":"SF Elena","year":"2010","journal-title":"Chaos"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ejps.2008.12.010","article-title":"Pharmacokinetic-pharmacodynamic relationship of NRTIs and its connection to viral escape: an example based on zidovudine.","volume":"36","author":"M von Kleist","year":"2009","journal-title":"Eur J Pharm Sci"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm0897-922","article-title":"The bottleneck in AZT activation.","volume":"3","author":"A Lavie","year":"1997","journal-title":"Nat Med"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1099\/vir.0.2008\/000273-0","article-title":"Restoration of the antiviral activity of 3\u2032-azido-3\u2032-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus by delivery of engineered thymidylate kinase to T cells.","volume":"89","author":"A Lavie","year":"2008","journal-title":"J Gen Virol"},{"key":"ref56","first-page":"113","article-title":"Intracellular interactions between nucleos(t)ide inhibitors of HIV re-verse transcriptase.","volume":"7","author":"AS Ray","year":"2005","journal-title":"AIDS Rev"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1385\/CT:4:2:155","article-title":"Phosphoryla- tion of thymidine and AZT in heart mitochondria: elucidation of a novel mechanism of AZT cardiotoxicity.","volume":"4","author":"EE McKee","year":"2004","journal-title":"Cardiovasc Toxicol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1042\/BJ20050749","article-title":"A computational model of mitochondrial AZT metabolism.","volume":"392","author":"PC Bradshaw","year":"2005","journal-title":"Biochem J"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/anie.200905651","article-title":"Crystal structure of HIV-1 reverse transcriptase bound to a non-nucleoside inhibitor with a novel mechanism of action.","volume":"49","author":"S Freisz","year":"2010","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1021\/jm801330n","article-title":"Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.","volume":"52","author":"M Radi","year":"2009","journal-title":"J Med Chem"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"12283","DOI":"10.1128\/JVI.00889-06","article-title":"Indolopyri- dones inhibit human immunodeficiency virus reverse transcriptase with a novel mech- anism of action.","volume":"80","author":"D Jochmans","year":"2006","journal-title":"J Virol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/nsmb.1937","article-title":"Initiation complex dy- namics direct the transitions between distinct phases of early hiv reverse transcription.","volume":"17","author":"S Liu","year":"2010","journal-title":"Nat Struct Mol Biol"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1126\/science.1163108","article-title":"Slide into action: dynamic shuttling of hiv reverse transcriptase on nucleic acid substrates.","volume":"322","author":"S Liu","year":"2008","journal-title":"Science"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1128\/JVI.02471-06","article-title":"Determination of the ex vivo rates of human immunodeficiency virus type 1 reverse transcription by using novel strand-specific amplification analysis.","volume":"81","author":"DC Thomas","year":"2007","journal-title":"J Virol"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nm1777","article-title":"Dose- response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs.","volume":"14","author":"L Shen","year":"2008","journal-title":"Nat Med"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"91ra63","DOI":"10.1126\/scitranslmed.3002304","article-title":"A critical subset model provides a conceptual basis for the high antiviral activity of major hiv drugs.","volume":"3","author":"L Shen","year":"2011","journal-title":"Sci Transl Med"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1110\/ps.072829007","article-title":"Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses.","volume":"16","author":"Q Xia","year":"2007","journal-title":"Protein Sci"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.virusres.2008.01.002","article-title":"Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors.","volume":"134","author":"N Sluis-Cremer","year":"2008","journal-title":"Virus Res"},{"key":"ref69","article-title":"A first course in stochastic processes","author":"S Karlin","year":"1975"},{"key":"ref70","article-title":"Markov chains","author":"JR Norris","year":"1998"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1097\/QAD.0b013e3282741feb","article-title":"Concen- trations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults.","volume":"21","author":"PL Anderson","year":"2007","journal-title":"AIDS"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1136\/jcp.34.10.1083","article-title":"Cell volumes of normal and malignant mononuclear cells.","volume":"34","author":"EH Chapman","year":"1981","journal-title":"J Clin Pathol"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/QAI.0b013e31815e7478","article-title":"Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV- infected patients.","volume":"47","author":"JJ Kiser","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/jac\/dkq447","article-title":"Pharma- cological considerations for tenofovir and emtricitabine to prevent HIV infection.","volume":"66","author":"PL Anderson","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00002030-200401230-00006","article-title":"Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients.","volume":"18","author":"F Becher","year":"2004","journal-title":"AIDS"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"40479","DOI":"10.1074\/jbc.M205303200","article-title":"Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir.","volume":"277","author":"AS Ray","year":"2002","journal-title":"J Biol Chem"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/095632020701800603","article-title":"The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mu- tants K65R, M184V and K65R+M184V.","volume":"18","author":"JK Ly","year":"2007","journal-title":"Antivir Chem Chemother"}],"container-title":["PLoS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pcbi.1002359","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T18:12:48Z","timestamp":1561227168000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1002359"}},"subtitle":[],"editor":[{"given":"Thomas","family":"Lengauer","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2012,1,19]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2012,1,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1002359","relation":{},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,19]]}}}